FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal By Ogkologos - June 20, 2025 591 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection February 7, 2025 Program Connects Adolescents and Young Adults to Quality Cancer Care October 24, 2024 ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ March 8, 2019 New “Microwave Mammography” Promises to be Safer, More Accurate, and Pain-Free September 19, 2019 Load more HOT NEWS Cancer Immunotherapy Drug Simultaneously Targets Two Proteins that Block Immune Response Feeding the Gut Studies Show Immunotherapy Improves Long-Term Survival in Growing Number of Cancers For Early-Stage Lung Cancer, Study Identifies Potential New Biomarker, Treatment Target
